{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:43:50Z","timestamp":1782247430547,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["222300420069"],"award-info":[{"award-number":["222300420069"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104279"],"award-info":[{"award-number":["82104279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371317"],"award-info":[{"award-number":["32371317"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277110"],"award-info":[{"award-number":["22277110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20416"],"award-info":[{"award-number":["U21A20416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["HZKY20220280"],"award-info":[{"award-number":["HZKY20220280"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.apsb.2024.03.028","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T07:38:22Z","timestamp":1711438702000},"page":"3624-3642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-9459","authenticated-orcid":false,"given":"Kai","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangli","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-643X","authenticated-orcid":false,"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.03.028_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2024.03.028_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc1837","article-title":"Protein-tyrosine phosphatases and cancer","volume":"6","author":"Ostman","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2024.03.028_bib3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2024.03.028_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.03.028_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","article-title":"The tyrosine phosphatase Shp2 in development and cancer","volume":"106","author":"Grossmann","year":"2010","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.028_bib6","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/med.21890","article-title":"Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery","volume":"42","author":"Song","year":"2022","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2024.03.028_bib7","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1055\/s-0042-1743411","article-title":"KRAS Q61H mutation confers cancer cells with acquired resistance to SHP2 inhibition","volume":"4","author":"Song","year":"2022","journal-title":"Pharmaceutical Fronts"},{"key":"10.1016\/j.apsb.2024.03.028_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2024.03.028_bib9","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.028_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.apsb.2024.03.028_bib11","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2024.03.028_bib12","series-title":"Handbook of cancer and immunology","first-page":"1","article-title":"Targeting SHP2 for cancer treatment: advances and prospects","author":"Song","year":"2022"},{"key":"10.1016\/j.apsb.2024.03.028_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2024.03.028_bib14","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.1c02008","article-title":"Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy","volume":"65","author":"Song","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib15","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/MCB.00646-09","article-title":"Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase\/AKT\/glycogen synthase kinase 3beta signaling","volume":"30","author":"Edouard","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2024.03.028_bib16","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.03.028_bib17","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.4049\/jimmunol.167.6.3391","article-title":"Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines","volume":"167","author":"Pathak","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2024.03.028_bib18","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1021\/jm400474r","article-title":"Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)","volume":"56","author":"Liu","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1124\/mol.106.025536","article-title":"Discovery of a novel SHP2 protein tyrosine phosphatase inhibitor","volume":"70","author":"Chen","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2024.03.028_bib20","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1073\/pnas.0710468105","article-title":"Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking","volume":"105","author":"Hellmuth","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.03.028_bib21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/cmdc.201500015","article-title":"Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u00a0vitro and in\u00a0vivo","volume":"10","author":"Grosskopf","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2024.03.028_bib22","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/jm8002526","article-title":"Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds","volume":"51","author":"Lawrence","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib23","doi-asserted-by":"crossref","first-page":"14780","DOI":"10.1021\/acs.jmedchem.0c01265","article-title":"From pyrazolones to azaindoles: evolution of active-site SHP2 inhibitors based on scaffold hopping and bioisosteric replacement","volume":"63","author":"Mostinski","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib24","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112657","article-title":"Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders","volume":"204","author":"Tang","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.03.028_bib27","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib28","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1021\/acs.jmedchem.7b01520","article-title":"Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment","volume":"60","author":"Xie","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acschembio.7b00980","article-title":"Dual allosteric inhibition of SHP2 phosphatase","volume":"13","author":"Fodor","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2024.03.028_bib30","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/acs.jmedchem.8b01726","article-title":"6-Amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors","volume":"62","author":"Sarver","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib31","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acs.jmedchem.8b01725","article-title":"Optimization of fused bicyclic allosteric SHP2 inhibitors","volume":"62","author":"Bagdanoff","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/acs.jmedchem.8b00513","article-title":"Small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2","volume":"62","author":"Wu","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib33","doi-asserted-by":"crossref","first-page":"15141","DOI":"10.1021\/acs.jmedchem.1c01132","article-title":"Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a potent and orally bioavailable SHP2 inhibitor","volume":"64","author":"Czako","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib34","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1016\/j.apsb.2022.09.022","article-title":"Harnessing the cyclization strategy for new drug discovery","volume":"12","author":"Tang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.03.028_bib35","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib36","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","article-title":"Allosteric SHP2 Inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.028_bib37","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1021\/acs.jmedchem.3c00483","article-title":"Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor designed for the treatment of solid tumors","volume":"66","author":"Taylor","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib38","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2024.03.028_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4155\/fmc-2023-0348","article-title":"Emerging therapeutic approaches of SHP2-targeted modulators","volume":"16","author":"Yang","year":"2024","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104788","article-title":"Novel PROTACs for degradation of SHP2 protein","volume":"110","author":"Zheng","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib42","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib43","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/acs.jmedchem.2c00063","article-title":"Discovery of a novel src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) and cyclin-dependent kinase 4 (CDK4) dual inhibitor for the treatment of triple-negative breast cancer","volume":"65","author":"Chen","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib44","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1021\/acs.jmedchem.2c00866","article-title":"Discovery of novel src homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor immunity","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/fmc-2021-0326","article-title":"Combining EGFR inhibitors with SHP2 or LSD1 inhibitors to overcome multidrug resistance in cancer","volume":"14","author":"Zhang","year":"2022","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib46","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.apsb.2020.10.021","article-title":"A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.03.028_bib47","article-title":"SHP2\u00a0allosteric inhibitor TK-453 alleviates psoriasis-like skin inflammation in mice via inhibition of IL-23\/Th17 axis","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.apsb.2024.03.028_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114106","article-title":"Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors","volume":"230","author":"Tang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.028_bib49","series-title":"Evaluation of enzyme inhibitors in drug discovery-A guide for medicinal chemists and pharmacologists","author":"Copeland","year":"2013"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T23:10:03Z","timestamp":1723072203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2211383524001217"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.03.028","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}